Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St set to open higher after June jobs report eases rate hike bets
- Oil falls for a third straight day after US, Iran conclude talks in Doha
- Dollar eases as yen gains ahead of US payrolls, chipmaker stocks struggle
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
June 6, 2016 5:40 PM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by... More
